MedPage Today (7/12) reports, “While use of pharmacogenomic testing reduced antidepressant prescriptions with known” medication-gene “interactions in patients with major depressive disorder (MDD), the effects on remission did not persist over time,” researchers concluded. The randomized trial revealed that “among over 1,900 patients, those in the pharmacogenomic-testing group were significantly less likely to be prescribed antidepressants with moderate (30% vs 54.6% in usual care) or substantial (10.7% vs 19.7%)” medication-gene interactions. The findings were published online July 12 in JAMA.
Related Links:
— MedPage Today (requires login and subscription)